Profiling of metalloprotease activities in cerebrospinal fluids of patients with neoplastic meningitis by Conrad, Catharina et al.
Profiling of metalloprotease
activities in cerebrospinal fluids of
patients with neoplastic meningitis
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Conrad, Catharina, Kristina Dorzweiler, Miles A. Miller, Douglas A.
Lauffenburger, Herwig Strik, and Jörg W. Bartsch. 2017. “Profiling
of metalloprotease activities in cerebrospinal fluids of patients
with neoplastic meningitis.” Fluids and Barriers of the CNS 14
(1): 22. doi:10.1186/s12987-017-0070-5. http://dx.doi.org/10.1186/
s12987-017-0070-5.
Published Version doi:10.1186/s12987-017-0070-5
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34375104
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Conrad et al. Fluids Barriers CNS  (2017) 14:22 
DOI 10.1186/s12987-017-0070-5
RESEARCH
Profiling of metalloprotease 
activities in cerebrospinal fluids of patients 
with neoplastic meningitis
Catharina Conrad1,2, Kristina Dorzweiler3, Miles A. Miller4,5, Douglas A. Lauffenburger4, Herwig Strik1* 
and Jörg W. Bartsch3*
Abstract 
Background: Neoplastic invasion into leptomeninges and subarachnoid space, resulting in neoplastic meningitis 
(NM) is a fatal complication of advanced solid and hematological neoplasms. Identification of malignant involvement 
of the cerebrospinal fluid (CSF) early in the disease course has crucial prognostic and therapeutic implications, but 
remains challenging. As indicators of extracellular matrix (ECM) degradation and breakdown of the blood–brain-
barrier, Matrix Metalloproteases (MMPs) and A Disintegrin and Metalloproteases (ADAMs) are potential analytes for 
cerebral pathophysiology and metastatic dissemination of tumor cells into the CSF.
Methods: We compared protease activities in CSF samples from patients with NM and control individuals using 
FRET-based metalloprotease substrates with distinct enzyme selectivity profiles in a real-time, multiplex approach 
termed “proteolytic activity matrix assay” (PrAMA). Protease activity dynamics can be tracked by fluorescence changes 
over time. By simultaneously monitoring a panel of 5 FRET-substrate cleavages, a proteolytic signature can be identi-
fied and analyzed to infer the activities of multiple specific proteases. Distinct patterns of substrate cleavage compar-
ing disease vs. control samples allow rapid, reproducible and sensitive discrimination even in small volumes of CSF.
Results: Individual substrate cleavage rates were linked to distinct proteases, and PrAMA computational inference 
implied increased activities of MMP-9, ADAM8 and ADAM17 (4–5-fold on average) in CSF samples from NM patients 
that were inhibitable by the metalloprotease inhibitor batimastat (BB-94). The activities of these proteases correlated 
with blood–brain barrier impairment. Notably, CSF cell counts were not found to directly reflect the protease activities 
observed in CSF samples from NM patients; this may explain the frequent clinical observation of negative cytology in 
NM patients.
Conclusion: PrAMA analysis of CSF samples is a potential diagnostic method for sensitive detection of NM and may 
be suitable for the clinical routine.
Keywords: Neoplastic meningitis, Metalloproteases, CSF, Real-time protease activities, FRET-substrates
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Leptomeningeal metastasis (LM) resulting in Neoplas-
tic Meningitis (NM) is a spread of malignant cells to the 
leptomeninges, the subarachnoid space and dissemina-
tion of tumor cells within the cerebrospinal fluid (CSF). 
NM is a complication of patients with progressive cancer 
(70%) and prognosis is poor once manifest NM with neu-
rological deficits develops [1]. Patients with breast can-
cer, lung cancer, malignant melanoma and hematopoietic 
neoplasms are affected most frequently [1, 2].
Recently, the combination of neurological examina-
tion, radiographic imaging of the neuroaxis and CSF 
cytology are used to diagnose NM [3, 4]. However, all 
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these techniques suffer from limitations and may only 
detect NM at an advanced stage of malignant CSF inva-
sion. CSF cytology has the highest specificity in diagnosis 
and detects tumor cells in the CSF in >95%, however the 
sensitivity of this method is generally less than 50% [3]. 
Depending on the quality of the cytospin preparation and 
the expertise of the clinical professional, the diagnostic 
accuracy of the CSF analysis is variable [2, 4]. Early diag-
nosis of NM as well as therapy monitoring is crucial for 
the patient outcome and an important prerequisite for 
disease control, since NM of solid tumors without ther-
apy progresses to death within 4–6  weeks accompanied 
by severe neurological symptoms [5, 6]. To overcome 
the lack of sensitivity, research has focused on biomark-
ers and characterization of tumor cells in the CSF [7–10]. 
Proteomic approaches attempted to relate differential 
CSF protein profiles obtained from mass spectrometry-
based studies to neoplastic diseases to identify potential 
biomarkers [11, 12]. Nevertheless, it is difficult to attrib-
ute disease identification and progression to a single pro-
tein. CSF profiling of the biological activity of multiple 
biomarkers may more accurately reflect the pathophysi-
ological processes than one biomarker, increasing speci-
ficity and sensitivity [13].
The metastatic invasion of tumor cells and dissemi-
nation to secondary sites is promoted by deregulated 
activity of extracellular metalloproteases (MPs), such as 
matrix metalloproteases (MMPs) and A Disintegrin and 
Metalloproteases (ADAMs). Both classes of proteases 
are members the metzincin superfamily, meaning that 
they utilize a complexed zinc ion in their catalytic site to 
constitute proteolytic activity. Major roles for MMPs and 
ADAMs in cancer progression have been reported, in 
particular, tumor cell invasion, angiogenesis and metas-
tasis [14, 15]. Cancer promoting protease function is part 
of a tightly regulated multidirectional network of numer-
ous proteolytic enzymes and their physiological inhibi-
tors, which is modulated context-dependent and involves 
proteolytic interactions of tumor, stromal and infiltrating 
immune cells [16]. The biological activities of MMPs and 
ADAMs in the context of neoplastic meningitis remain 
less clear but likely given the dissemination of tumor cells 
through the Virchow–Robin space into the CSF as out-
lined (Additional file 1: Fig. S1). The occurrence of extra-
cellular proteases in the CSF has been reported under 
various pathological conditions of the brain including 
infection [17–21], inflammation [22–26], neurodegen-
eration [27–32], ischemia [33, 34] and neoplasm [35, 36]. 
Proteolytic enzymes involved in the disturbance of tissue 
integrity and the penetration of tumor cells into the suba-
rachnoid space could serve as diagnostic markers for NM 
[37, 38]. Thus, the analysis of specific patterns of protease 
activation in the CSF may reflect whether a condition is 
benign or malignant, and may be a suitable approach for 
specific and sensitive detection of NM.
In order to obtain metalloprotease profiles for 
patients with NM in a pilot study, we utilized a multi-
plex approach for simultaneous detection of MMP and 
ADAM activities in the CSF of patients with NM com-
pared to control individuals and tumor patients without 
NM. The Proteolytic Activity Matrix Analysis (PrAMA) 
is a combined experimental and mathematical method 
based on time-lapse fluorescence measurements of a 
panel of moderately specific FRET-based polypeptides in 
small volumes of biological samples. The observed cleav-
age patterns are compared to a standard table of catalytic 
efficiencies measured from purified mixtures of recom-
binant metalloproteinases and should reflect changes in 
specific enzyme activities [13, 39] in CSF samples from 
patients affected by NM.
Methods
Recruitment of patient cohorts and collection 
of cerebrospinal fluid (CSF)
This pilot study obtained ethical approval from the local 
Ethics Committee (Marburg University; File No. 101/15). 
Informed consent was provided from patients to use 
their biological specimens and clinicopathological data 
for research purposes. No selection criteria were applied, 
i.e. all available patients with suspected diagnosis of NM 
and with brain metastases undergoing routine lumbar 
puncture were recruited into the study. CSF samples in 
the control group were collected during therapeutic lum-
bar punctures from patients with normal pressure hydro-
cephalus (3/12) or idiopathic intracranial hypertension 
(9/12). Patients with normal CSF cytology and blood–
brain-barrier (BBB) physiology without clinical evidence 
for neuro-infectious, neuro-inflammatory, neuro-degen-
erative or neoplastic brain pathologies were considered as 
controls. All CSF samples were collected at the Depart-
ment of Neurology, Philipps University Marburg, Ger-
many. Lumbar puncture to collect CSF was performed 
by medical staff according to clinical guidelines. Upon 
collection, CSF served primarily for diagnostic purposes, 
remaining CSF was placed on ice and centrifuged at 
1000g to remove cells. Clarified CSF was aliquoted, snap-
frozen in liquid nitrogen and stored at −80 °C for further 
analysis. Clinicopathological features were documented 
pseudonymized, patients were grouped in control indi-
viduals (crtl), patients with neoplastic meningitis (NM) 
and patients with brain metastases without neoplastic 
meningitis (w/o NM) according to neurological examina-
tion, contrast-enhanced MRI of the brain and neuroaxis 
and CSF cytology for clinical diagnosis.
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Determination of MMP/ADAM activities in CSF
Cell-free cerebrospinal fluids were tested for MMP/
ADAM activity by using the Proteolytic Activity Matrix 
Analysis (PrAMA) technique developed by Miller et  al. 
using FRET-based polypeptide substrates PEPDab005, 
PEPDab010, PEPDab008, PEPDab013 and PEPDab014 
(BioZyme Inc, Apex, NC), which vary in their specifi-
cities towards different ADAM family members and 
MMPs. PrAMA analysis was performed as described 
earlier [13, 39]. Briefly, for time-lapse fluorimetry, a final 
substrate concentration of 10  μM (diluted from 5  mM 
stock in DMSO) in 50 μl of activity buffer (1 μM  ZnCl2, 
20 mM Tris–HCl pH 8.0, 10 mM  CaCl2, 150 mM NaCl, 
6 × 10−4% Brij-35) was incubated with 50 μl of CSF using 
96-well microtiter white opaque plates, each sample was 
run in technical triplicates. Samples containing sufficient 
volumes were included for inhibitor studies and repeti-
tive measurements. To some samples, the broad-range 
MMP/ADAM inhibitor batimastat (Tocris Bioscience, 
Bio-Techne, Wiesbaden, Germany) was added at a con-
centration of 1  μM dissolved in DMSO. Fluorescence 
units versus time were monitored with a Fluostar BMG 
Optima using excitation and emission wavelengths of 485 
and 530 nM at 37  °C, respectively. A non-linear model 
was used for curve fitting as described previously [13], 
the signal of a negative control was subtracted (FRET-
substrate only) and time-lapse fluorimetry data were 
normalized to a positive control (0.01% Trypsin). Specific 
protease activities were inferred with PrAMA by com-
paring the pattern of substrate cleavage rates for each 
sample to a matrix of known substrate specificities for 
ADAM8, ADAM17, MMP-2 and MMP-9 that was deter-
mined using purified enzymes [13]. All calculations and 
statistical evaluation of data was conducted using Matlab 
(2014b, MathWorks, Natick, MA).
Statistical analysis
The increase in fluorescence resulting from substrate 
proteolysis was tracked every 5 min for 4 h. For interpre-
tation of time-lapse fluorimetry data, a non-linear curve-
fitting model that accounted for substrate depletion and 
photobleaching decay served to determine cleavage rates. 
Cleavage rates are all presented in heat maps averaged 
over technical triplicates, clear outliers were excluded 
using Dixon’s Q-Test with a 90% threshold. PrAMA 
inference was performed as described previously with 
30% sampling error and threshold σT =  1.4 [13]. Based 
on normal distribution of values as tested by the David 
test at the significance level p =  90%, statistical signifi-
cance was determined using a two-tailed unpaired Stu-
dent’s t test to compare two sample groups. To compare 
more than two experimental groups, Analysis of Variance 
(ANOVA) was used. Values are denoted as not significant 
(ns, p ≥ 0.05), significant * (p ≤ 0.05), highly significant ** 
(p ≤ 0.01), or very highly significant *** (p ≤ 0.001).
To group the generated datasets, observed average 
cleavage rates were hierarchically biclustered mean-cen-
tered and variance-normalized by row, using Euclidean 
distance, average linkage and optimal leaf order. Clear 
patterns emerging from cluster analysis are indicated by 
dendrograms flanking the array.
To investigate the relationship between CSF cell count, 
blood–brain-barrier impairment and protease activi-
ties, Pearson’s correlation coefficients (r) were calculated 
between these parameters, respectively. Statistical sig-
nificance (p) was determined as described in the section 
above.
Results
Patient groups
According to the clinical diagnosis of medical profes-
sionals at the department of Neurology, patients were 
assigned to one of three groups: patients with neoplastic 
meningitis (NM, n  =  12), patients with brain metasta-
ses but without leptomeningeal tumor spread (w/o NM, 
n = 12) or controls (ctrl, n = 12). CSF controls were char-
acterized by normal CSF cytology, physiological protein 
concentrations, normal albumin and immunoglobulin 
quotients and absence of oligoclonal IgG bands, thus 
excluding inflammation, infection and impairment of 
the blood–brain-barrier. Comparison of baseline demo-
graphics for each group did not show significant differ-
ences. The mean age was 58.0 years (range 48–60 years) 
for patients with NM, 53.5 years (range 24–75 years) for 
patients with brain metastases w/o NM and 41.2  years 
(range 20–68  years) for controls. In our patient cohort, 
the NM cases were solely from female patients (gender 
male/female: NM 0/12) since NM is most prevalent in 
breast cancer patients. Accordingly, we recruited patients 
w/o NM and control group as far as possible from other 
female patients so that the proportion of female patients 
was higher than males (gender male/female: w/o NM 3/9 
and crtl 1/11).
Protease activity is increased in the CSF of patients 
with neoplastic meningitis
Clinically obtained CSF samples from controls, patients 
with NM and patients with brain metastases but no lep-
tomeningeal metastasis were subjected to time-lapse 
fluorimetry and analyzed for substrate cleavage rates 
of FRET peptides PEPDab 5, 8, 10, 13 and 14 in parallel 
(Fig. 1a; Additional file 1: Table S1). Distinct patterns of 
protease activity for disease and control samples were 
found. Overall, the observed reaction rates showed the 
strongest activity with PEPDab#10, which is most effi-
ciently cleaved by ADAM17 [13]. Second strongest 
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substrate cleavage was detected for PEPDab#8, which is 
most selective for MMP-9. We discovered that enzymatic 
activity tracked by time-lapse fluorimetry increased in 
the CSF of patients with NM, whereas cleavage rates in 
the CSF of control individuals and patients with brain 
metastases w/o NM were similar and remained close to 
background fluorescence. Cleavage rates in the CSF were 
significantly different between ctrl and NM, as well as 
between NM and w/o NM for all PEPDab substrates ana-
lysed (p = 0.01 for PEPDab 5; p = 4.2 × 10−6 for PEPDab 
8; p = 0.00013 for PEPDab 10; p = 0.09 for PEPDab 13; 
p = 0.0009 for PEPDab 14) whereas there were no signifi-
cant changes detectable between crtl and patients with 
brain metastatic cancer w/o NM.
Resulting sample cleavage patterns were hierarchically 
bi-clustered, mean-centered and variance-standardized 
using Euclidean distance, average linkage and optimal 
leaf ordering (Fig. 1b). This type of cluster analysis groups 
88% of the NM CSF samples in two main clusters as indi-
cated by the dendrogram flanking the array; in contrast, 
substrate cleavage patterns in CSF samples of control 
individuals and patients with brain metastases w/o NM 
cluster closely together with no clear pattern. Of the 
NM CSF samples, sample#75 is the only one that does 
integrate into the group of neoplastic meningitis. These 
results suggest that disease samples can be clearly distin-
guished from control samples by their substrate cleavage 
signature.
Inference of protease identities in CSF samples revealed 
by the PrAMA method
Individual time-lapse measurement derived from rela-
tively non-specific FRET-substrates can not generally be 
understood to relate to specific proteases. To address this 
issue, PrAMA inference uses panels of FRET-substrate 
cleavage measurements, coupled with known catalytic 
efficiencies previously determined with recombinant 
enzymes [13], Fig.  2a), to elucidate particular enzyme 
activities from cleavage signatures obtained in clinical 
samples containing multiple proteases. PrAMA infer-
ence is strengthened by comparison of reaction rates 
in the presence and absence of specific inhibitors [13]. 
We analyzed all CSF samples using a set of five PEPDab 
substrates along with the broad-spectrum MP inhibitor 
batimastat (BB-94). Addition of 1 μM BB-94 reduced the 
observed rates by at least 50% on average, supporting 
that although MMP and ADAM activities are the major 
components of the observed substrate cleavage, other 
non-MMP/ADAM protease activities are present in the 
samples (Fig. 2b). PrAMA inference of specific protease 
activities revealed significant differences between crtl and 
NM for MMP-9 (4.5-fold, p = 9.9 × 10−6), ADAM8 (4.7-
fold, p = 0.00054) and ADAM17 (4.8 fold, p = 0.00051). 
Changes for MMP-2 were not significant, ADAM10 was 
not identified in the enzyme composition of the CSF 
samples by PrAMA. Of the proteases identified, PrAMA 
inference suggests the activities of MMP-9 and ADAM17 
were the highest on average (Fig. 2c). To confirm that the 
observed peptide cleavage patterns are correlated with 
NM and not with a general presence of a malignancy, we 
included a patient cohort in our analyses with metastases 
but without leptomeningeal involvement.
Substrate cleavage patterns in CSF in follow‑up lumbar 
CSF punctures
Following initial diagnosis of NM, patients are undergo-
ing regular follow-up lumbar punctures in the clinical 
routine for intrathecal chemotherapeutic treatment and 
monitoring of disease progression. CSF samples obtained 
from patients who underwent 2-month follow-up lumbar 
punctures with cytologically proven stable diagnosis were 
subjected to PrAMA to demonstrate reproducibility of 
results. For all patient samples analyzed, substrate cleav-
age patterns in the CSF remained similar compared to 
baseline cleavage (Fig. 3a). Consistently, the inferred pro-
tease activities resembled baseline activities for ADAM8, 
a b
Fig. 1 Analysis of protease activities in the CSF of three patient 
cohorts. Cleavage signatures in CSF samples were analyzed from 12 
control individuals (crtl), 12 patients with neoplastic meningitis (NM) 
and 12 patients with brain metastases of different primary tumors, 
but without neoplastic meningitis (w/o NM). Protease activities in 
real-time mode were determined using PEPDab substrates 5, 8, 
10, 13 and 14 at final concentrations of 10 µM for 4 h. Heat map 
summarizing mean cleavage rates of 3 technical replicates for each 
clinical samples calculated from time-lapse fluorimetry a. Hierarchical 
bi-clustering result corresponding to (a), with data mean-centered 
and variance-normalized by row. CSF cleavage patterns of patients 
with NM (labeled red) cluster closely together, control individuals and 
patients with brain metastases w/o NM group together without form-
ing main clusters for each condition (b)
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a
b
c
Fig. 2 Inferred protease activitity of MMP-9, ADAM8 and ADAM17 in CSF is increased in neoplastic meningitis. Catalytic efficiencies for FRET-based 
peptide substrates have been determined previously across a panel of purified recombinant enzymes [13]. Observed cleavage efficiencies for 
MMP-2, MMP-9, ADAM8 and ADAM17 for PEPDab Substrates 5, 8, 10, 13 and 14 (modified from [13] are shown a. Effects of broad-spectrum MMP-
inhibitor batimastat (BB-94+) treatment on observed substrate cleavage in representative CSF samples. Combination of specific substrates and 
inhibitors allow to infer protease activities accurately (b). PrAMA inferred the cleavage signatures from (Fig. 1a), using parameters from (a). PrAMA 
inference results in CSF in patients with NM were compared to control individuals and patients with brain metastases w/o NM. The box indicates 
the interquartile range, blue bar indicates the median, red bar denote the mean values and whiskers indicate the 95% confidence interval. Open dots 
represent the individual samples (o), extreme values are marked with asterisks. Inferred differences were statistically significant for MMP-9, ADAM8 
and ADAM17, stars indicate * p <0.01; ** p <0.005, *** p <0.001 (c)
a b
Fig. 3 PrAMA inference results are reproducible in follow-up lumbar punctures (LP). Substrate cleavage patterns in CSF samples obtained from 
same patients with unchanged clinical diagnosis within a time period of 2 months, baseline substrate cleavage in CSF is denoted as LP 0, cleavage 
rates in CSF of 2-month follow-up (F/U) lumbar punctures as LP F/U. Substrate cleavage is shown for controls (ctrl), patients with neoplastic men-
ingitis (NM) and patients with brain metastases w/o NM in a heatmap (a). PrAMA inferred the cleavage signatures from (Fig. 2a), using parameters 
from (a). Calculated protease activities are presented as bar graph (light grey, control individuals; grey, NM; black, w/o NM), error bars indicate stand-
ard deviation of three technical replicates, dotted columns denote 2-months follow-up lumbar punctures, respectively (b). Note that both, cleavage 
patterns and PrAMA inference results, remain similiar for controls, NM and the patient with brain metastases w/o NM. Two-tailed, one-sample t test 
was used to compare initial protease activities with 2-month follow-up measurements, values were not significant (ns, p ≥ 0.05) or significant * 
(p ≤ 0.05)
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ADAM17 and MMP-9 as observed in the respective CSF 
(Fig. 3b).
Correlation of protease activities with CSF cell counts 
and BBB disturbance
Conflicting results concerning the relationship of pro-
tease expression and CSF cell count have been reported 
for certain MMPs, and so far, only few studies have inves-
tigated the biological activity of proteases in CSF. For 
MMP-9, there were studies describing either a positive or 
a non-linear correlation of protein levels, CSF cell count 
and blood–brain-barrier impairment in various neuro-
logical diseases [21, 24, 27, 40].
To overcome this problem, we sought to use the 
PrAMA method that allows for sensitive detection of 
biochemical parameters reflecting the process of cellu-
lar invasion into the leptomeningeal space. Therefore we 
analyzed 16 patients presenting with pleocytosis in CSF 
cytology, including patients with neurological patholo-
gies other than NM, to elucidate the relationship between 
substrate cleavage, cell count and CSF/serum albumin 
ratio, a routine parameter indicating blood–brain-barrier 
disturbance. Pearson’s correlation statistics revealed a 
significant correlation of substrate cleavage rates and BBB 
impairment (expressed by the QAlb, albumin quotient) 
with a high to good correlation coefficient (r) depending 
on the inclusion of one patient (Additional file 1: Figs. S2 
and S3). In contrast, cleavage rates and CSF cell count 
did not correlate, as no correlation coefficient was higher 
than 0.075 (Additional file 1: Fig. S3). The cellular source 
of the observed protease activity remains unclear; how-
ever, our results indicate that mere appearance of certain 
cell populations in the CSF does not reflect their biologi-
cal activation. Notably, increased, uncontrolled MMP 
activation is implicated to play crucial roles in cerebral 
pathophysiology by mediating disruption of the blood–
brain-barrier integrity and worsening the outcome [37, 
38, 41]. In accordance, BBB disruption may be a result of 
increased protease activity in the CSF and vice versa.
Therapeutic progression monitoring of neoplastic 
meningitis by PrAMA
The key factor in the outcome of NM is early diagnosis, 
because even though clinically manifest NM is treated 
aggressively with a combination of radiation, systemic 
and intrathecal chemotherapy, therapy is palliative with 
the goal to extend survival and improve neurologic symp-
toms [6]. In order to evaluate whether PrAMA can be 
used to monitor therapy outcome, a case of a 62-year 
old breast cancer patient with leptomeningeal metastasis 
was assessed with collection of CSF samples before treat-
ment and 3 months after intrathecal chemotherapy with 
liposomal cytarabine (cytosine arabinoside, araC, Fig. 4). 
Following treatment with araC for 3  months, substrate 
cleavage rates and inferred protease activities decreased 
by 2.3-, 2.4.- and fourfold for ADAM8, MMP-9 and 
ADAM17, respectively, after intrathecal treatment with 
araC, whereas the MMP-2 activity was not significantly 
changed. Coincidently the status of the patient appeared 
stable over 2  years together with continuously low pro-
tease activities. Thus, protease activity profiles may have 
clinical implementation to sensitively monitor treatment 
efficacy and disease progression (Fig. 4).
Discussion
Since abnormalities on MRI or in CSF require a sub-
stantial extent of disease in the case of leptomeningeal 
metastasis, it is likely that treatment delay due to the 
insensitivity of current methodologies contributes to the 
poor prognosis in NM. On the molecular level, CSF is a 
heterogeneous mixture of a low number of leukocytes, 
debris, small amounts of soluble protein, and tumor 
cells in the case of NM. The cellular components in the 
CSF are an important source of proteins determining the 
course of the disease relevance. Small molecules deriv-
ing from the brain or the blood reach the CSF compart-
ment via diffusion. Conventional analytic approaches 
such as ELISA or Western Blot are often not suitable to 
detect low-abundance protein biomarkers in the CSF, 
which is characterized by a very low concentration of 
proteins. Compositional mass spectrometry-based prot-
eomic studies of the CSF help to gain insight into dynamic 
disease-related changes, but generally are too complex for 
clinical routine [42]. Here we attempted to overcome this 
diagnostic constraint by providing a sensitive method of 
detecting increased proteolytic activities in small volumes 
of CSF samples only in NM patients with a reproducible 
and significant difference to samples from patients with 
brain metastasis and control patients.
MMP2, MMP-9, ADAM8, and ADAM17 are increased 
in CSF samples from NM patients. For a single case of a 
clinically stable patient, that is with no signs of impair-
ment based on cytology, MRI and neurological exami-
nation, we observed almost similar activity values with 
the exception of MMP-2, which slightly increased in 
the follow-up sample. Moreover, in another patient 
treated intrathecally with the antimetabolite cytarabine, 
the increase of MMP-2 and all other proteases exam-
ined could be reverted, suggesting that the therapeutic 
progress is reflected by a decrease in MMP and ADAM 
activities as observed here.
Although we can clearly distinguish CSF samples 
from NM patients in contrast to control individuals and 
patients with brain metastases, the result of the PrAMA 
analysis has some limitations: firstly PrAMA inference 
suggests a major contribution of distinct proteases to the 
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observed metalloprotease activities, as they can be par-
tially inhibited by BB-94 that works on MMP-2, MMP-
9, ADAM8, ADAM17; secondly, based on activities not 
inhibited by BB-94, we postulate protease activities other 
than metalloproteases present in CSF samples.
With respect to the identity of the metalloproteases, we 
have attempted to confirm their presence by ELISA. Only 
in a very severe case of NM, a 53-year old patient with 
progressive breast cancer with severe neurologic defi-
cits and diagnosis based on CSF cytology, we were able 
to detect MMP-9 and TNF-RI (as ADAM17 substrate) 
by ELISA (Additional file 1: Fig. S4). From this CSF sam-
ple, activities determined by PrAMA were up to 10-times 
higher than in all other NM cases. According to Dixon’s 
Q-Test, this sample was defined as outlier and excluded 
from cluster analysis. Clusters of atypical, malignant cells 
dominated the cytogram and the blood–brain-barrier 
function was strongly impaired as determined by an 
albumin quotient of 80.4. Although multimodal treat-
ment was initiated immediately, NM in this patient pro-
gressed to death within 3 months.
Although our results provide pilot data for the high 
impact of CSF profiling in disease at present, they under-
score the value of multiplexing, i.e. with respect to a micro-
fluidic platform [43] and to a series of other diseases related 
to CSF changes. Future studies in larger patient cohorts are 
required to validate our preliminary results. Mechanisti-
cally, invasion of malignant cells into the leptomeninges 
and the CSF is a multistep process that requires differen-
tial expression of migration- and invasion-related proteins. 
On a time scale, disease-related changes in the composition 
of the CSF are expected to precede transmigration of cells 
into the CSF. Most likely, the proteolytic activity in the CSF 
may increase before pathological signs can be detected by 
MRI or CSF cytology. The case of a 62 year-old patient with 
minimal CSF involvement from breast cancer surviving 
more than two years, which is described before, underlines 
the clinical experience that early detection and subsequent 
treatment of malignant cells in the CSF is crucial for long-
term control of neoplastic meningitis. Very early detec-
tion of subclinical CSF invasion may therefore be crucial to 
improve the otherwise frustrating results of NM treatment.
Clinical data known to date implicate that conventional 
therapies are not sufficient to achieve long-term control or 
remission in cases of neoplastic meningitis (Strik, Proem-
mel 2010). Molecularly targeted therapies that aim at pre-
venting tumor cells from invasion into the CSF space may 
offer more efficacy. At present, several pharmacological 
inhibitors of MPs are already available and ADAM-inhib-
itors are being developed. After a more detailed analysis 
a b
Fig. 4 Protease activity decreases following intrathecal treatment with liposomal cytarabin. In a 62-year old breast cancer patient with leptome-
ningeal metastasis, protease activities were analyzed prior and after intrathecal treatment with liposomal cytarabin. Time-lapse fluorimetry output 
of the same patient with neoplastic meningitis arising from breast cancer previous (NM, black dots) and following treatment of NM with Cytara-
bin (araC) (NM + AraC, grey dots) for 3 months. Substrate tracking (PEPDab 5, 8, 10, 13 and 14) for 30 min averaged over 3 technical replicates is 
shown, dashed line indicates the negative control. Cleavage rates were calculated as described previously using a non-linear kinetic model to fit the 
time-lapse data (a). PrAMA inference results for samples analysed in A, using significance threshold σT = 1.4. Error bars indicate standard deviation 
of technical triplicates (b). Two-tailed, one-sample t test was used to compare cleavage rates pre and post treatment with araC. Values were not 
significant (ns, p ≥ 0.05), significant * (p ≤ 0.05) or highly significant ** (p ≤ 0.01)
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of the pathophysiological mechanisms, pharmacological 
inhibition of MPs and ADAM proteins may be efficient 
tools to prevent or treat malignant CSF-invasion.
In this respect, our results from a multiplexed assay 
provide a novel perspective into MMP/ADAM contribu-
tion to the pathophysiology of NM. More importantly, 
the simple profiling of protease activities in CSF samples 
from patients with medical indications seems to reflect 
individual context-dependent protease function in inva-
sive diseases and should be explored in a larger cohort 
of NM patients but also in other clinical applications 
including infectious diseases in the CNS.
Conclusion
Based on these pilot data we demonstrated that the 
simultaneous detection of metalloprotease activities in 
CSF samples by the PrAMA method could be of diagnos-
tic value to distinguish NM from metastasis without NM 
and from controls with normal CSF. The observed cleav-
age profiles are consistently present in patients with a 
positive follow-up analysis and are modulated by success-
ful treatment of NM. Moreover, we detected ADAM8, 
MMP-9, and ADAM17 activities in the CSF as major 
analytes in the CSF of patients with NM.
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